key: cord-0258115-h2l54vyv authors: Yang, W.; Greene, S.; Peterson, E. R.; Li, W.; Mathes, R.; Graf, L.; Lall, R.; Hughes, S.; Wang, J.; Fine, A. title: Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant date: 2021-08-07 journal: nan DOI: 10.1101/2021.08.04.21261596 sha: ddbfb6ad851009420c90745663eab0c0d33141c2 doc_id: 258115 cord_uid: h2l54vyv Background: The B.1.526 variant (WHO designation: Iota) is a SARS-CoV-2 variant of interest, as classified by both the US CDC and the WHO. Due to a lack of extensive genomic sequencing and contact tracing data, its key epidemiological properties have not been well characterized. Methods: We utilized nine epidemiological and population datasets collected in New York City (NYC), where B.1.526 emerged, and comprehensive modeling to estimate the changes in transmissibility, immune escape potential, and infection fatality risk (IFR) for B.1.526. Findings: Estimated transmission rate in the neighborhood where B.1.526 was initially detected was consistently higher than other neighborhoods in NYC and further increased during the weeks preceding B.1.526 detection, likely due to its early spread there. Overall, models estimated that B.1.526 had transmissibility about 15-25% higher than previously circulating variants and that it could escape immunity in 0-10% of previously infected persons. In addition, B.1.526 substantially increased IFR in older adults: by 46% (95% CI: 7.4 - 84%) among 45-64 year-olds, 82% (95% CI: 20 - 140%) among 65-74 year-olds, and 62% (95% CI: 45 - 80%) among 75+ during Nov 2020 - Apr 2021, compared to baseline IFR estimated for preexisting variants. Interpretation: New variants like B.1.526 likely spread in the population weeks prior to detection, and partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19 pandemic response as it remains a global public health threat. The SARS-CoV-2 virus spread quickly worldwide in early 2020, causing the COVID-19 pandemic. For the network model-inference system, we utilized multiple sources of epidemiological data, 116 including confirmed and probable COVID-19 cases, emergency department (ED) visits, and 117 deaths, as well as vaccination data. As done previously, 6 we aggregated all COVID-19 confirmed 118 and probable cases 7,8 and deaths 8 reported to the NYC Department of Health and Mental 119 Hygiene (DOHMH) by age group (<1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-74, and 75+ year-olds), 120 neighborhood of residence (42 United Hospital Fund neighborhoods in NYC 9 ) and week of 121 occurrence (i.e., week of diagnosis for cases or week of death for decedents). COVID-19-related 122 ED visit data were obtained from the NYC syndromic surveillance system, comprised of all 53 123 hospital EDs in the city. 10 This system identified individuals presenting at the EDs with COVID-124 like-illness (CLI; defined as having a fever and cough or sore throat or respiratory illness, or 125 pneumonia, or a COVID-19 discharge diagnosis code, excluding those with a discharge diagnosis 126 code of influenza only); in addition, CLI patients were matched to electronic laboratory reports 127 of SARS-CoV-2 tests with diagnosis date within ±7 days of ED visit. We estimated the number of 128 COVID-19-related ED visits as the number classified as CLI multiplied by the percentage of those 129 who tested positive for SARS-CoV-2 RNA, stratified by the same age and neighborhood groups 130 in weekly intervals. To account for the impact of vaccination, we also included COVID-19 131 vaccination data (partially and fully vaccinated, separately), aggregated to the same 132 age/neighborhood strata by week. In addition, as in our previous study, 6 we used mobility data from SafeGraph 11 to model 135 changes in SARS-CoV-2 transmission rate due to non-pharmaceutical interventions. These data 136 were aggregated to the neighborhood level by week without age stratification. For the multi-variant model analysis, we additionally utilized four city-level, weekly datasets: 1) [1] where Si, Ei, Ii, Ri, and Ni are the number of susceptible, exposed (but not yet infectious), 161 infectious, and removed (either recovered or deceased) individuals and the total population, 162 respectively, from a given age group in neighborhood-i. 2 3'45 is the average citywide 163 transmission rate; bs is the estimated seasonal trend. 6 The term bi represents the 164 neighborhood-level transmission rate relative to the city average. The term mij represents the 165 changes in contact rate in each neighborhood (for i=j) or spatial transmission from 166 neighborhood-j to i (for i≠j) and was computed based on the mobility data. 6 Z, D, and L are the 167 latency period, infectious period, and immunity period, respectively. The term vi,1 represents 168 the number of individuals in neighborhood-i successfully immunized after the first dose of the 169 vaccine and is computed using vaccination data and vaccine efficacy (VE) for 1 st dose; vi,2 is the 170 additional number of individuals successfully immunized after the second vaccine dose 171 (excluding those successfully immunized after the first dose). Because 97% of vaccine doses 172 administered in NYC during our study period (through April 30, 2021) were the Pfizer-BioNTech 173 or Moderna vaccines, we assumed a VE of 85% fourteen days after the first dose and 95% seven 174 days after the second dose based on clinical trials and real-word data. 14 Table S2 ). We restricted this simulation to Nov 2020 -Apr 2021 (i.e., from the initial identification of 211 B.1.526 to before the further detection and increase of other variants such as Gamma and 212 Delta). In addition to preexisting variants of SARS-CoV-2 prior to Nov 2020 (hereafter referred 213 to as "non-VOC/VOI variants" for simplicity) and B. Table 217 S2. For simplicity, we did not account for other VOCs/VOIs variants because their percentages 218 were very low during either analysis period. 13 219 220 Initial analysis based on the model-inference estimates suggested B.1.526 was around 20% 221 more infectious than non-VOC/VOI variants, without accounting for changes in immunity due to 222 potential immune escape (see details in Results). Therefore, in this analysis, we tested 223 combinations of change in transmissibility ranging from 10 -30% increases and immune escape 224 ranging from 0 -30%, both with a 5% increment and ±5% intervals (35 combinations in total). 225 For instance, for the combination centering at 10% transmissibility increase and 0% immune 226 escape, the model is initialized using values in the range of 5-15% (i.e., 10 ± 5%) transmissibility 227 increase and 0-5% (i.e., 0 ± 5% and setting negatives to 0) immune escape. In addition, due to 228 uncertainty on the initial prevalence, we tested three different levels of initial seeding for the 229 week starting Nov 1, 2020, i.e., low (0.5 -2.5%), high (1.5 -3.5%), and wider range (0.5 -3.5%). 230 For reference, Washington Heights -Inwood (WHts), which is the neighborhood where the first 231 patients identified with B.1.526 resided and sought care, constituted 3.2% of the NYC 232 population in 2018. We initialized the model using the model-inference estimates (e.g., 233 population susceptibility and transmission rates by age group; Table S2 ) and ran the model for 234 each parameter combination 10 times, each with 1000 realizations to account for model 235 stochasticity. Results are summarized from the 10,000 model realizations. To identify the most plausible combination of transmissibility and immune escape properties 238 for B.1.526, we compared the model-estimated weekly number of cases, hospitalization, and 239 deaths as well as the percentage of the variants to available data. Evaluation was made based 240 on 1) accuracy, i.e., if the observation falls within the model-estimated interquartile range, it is 241 deemed accurate; 2) relative root-mean-square-error (RMSE) between the observed and the 242 model-estimated; and 3) Pearson correlation between the two time-series. Because results 243 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In both models, IFRcombined is the overall IFR for each week, estimated using the model-inference week, estimated using the multi-variant age-structured model with the most plausible 264 parameter combination as data are not available. IFRbaseline is the baseline IFR for the preexisting 265 variants, set to the average of model-inference estimates over the period of Oct -Nov 2020 266 (i.e., prior to the increase of the new variants). The variant-specific IFRs, IFRB.1.526 and IFRB. 1.1.7, 267 are then estimated using the regression models (n = 14 weekly data points for Model 1; and n = 268 26 weekly data points for Model 2). For either model, the change in IFR due to a given variant is 269 then computed as: 270 Both model analyses were performed for each age group or all ages combined, separately; we 272 also combined all those aged under 25 as the IFRs were similarly low for the four sub-age 273 groups (i.e. <1, 1-4, 5-14, and 15-24 year-olds). 274 275 Epidemic dynamics of the second pandemic wave in NYC 277 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint NYC experienced a very large first pandemic wave during spring 2020. Similar to our previous 278 work, 6 the model-inference system here estimates that 16.6% of the population (95% CrI: 13.6 279 -21.5%; or 1.1 -1.8 million people) had been infected by the end of May 2020 (i.e., end of the 280 first wave; Fig 2D) . The city was able to gradually reopen part of its economy during summer 281 2020 after a 3-month long stay-at-home mandate for all non-essential workers. However, 282 infection resurged beginning in the fall of 2020 and the city experienced a second pandemic 283 wave around Nov 2020 -April 2021 (Fig 2) . Following the second wave, an estimated total of sequenced by end of Feb 2021). In comparison, the estimates were relatively stable for other 303 neighborhoods (Fig 3A) , suggesting the changes in WHts were likely due to the early spread of 304 B.1.526. Averaging over this period, we estimate that the relative transmission rate in WHts 305 increased by 8.4% (95% CI: -5.8 -22.5%). Concurrently, the citywide transmission rate 306 increased by 13.3% (95% CI: -21.1 -47.8%; Fig 3B) . These two preliminary estimates in 307 combination suggest that the transmission rate of B.1.526 likely is 22.8% (95% CI: -12.4 -308 58.0%) higher than preexisting non-VOC/VOI variants, without accounting for potential change 309 due to immune evasion. 2.5%, 1.5 -3.5%, and 0.5 -3.5%), model simulations consistently show that B.1.526 likely 316 increases transmissibility by 15-30% and can escape immunity in 0-10% of previously infected 317 persons (Fig 4 A-C) . Overall, a higher initial prevalence (1.5 -3.5% at the beginning of Nov 2020) 318 combining with a 15-25% increase in transmissibility and 0-10% immune escape (Fig 4 During the second wave, estimated IFR increased gradually in later months, particularly among 328 older age groups, despite the decline in deaths following mass-vaccination (Fig 5 This latter finding appears to be consistent with the report by Annavajhala et al. 2 showing 371 resistence of B.1.526 to therapeutic antibodies. Over the course of the pandemic, SARS-CoV-2 372 IFR has decreased substantially (about a 3-fold difference between the two pandemic waves), 373 likely due to improved medical treatments (e.g., therapeutic antibodies), better patient 374 management, and earlier diagnosis. As older adults are more likely to suffer from severe 375 COVID-19 and thus receive therapeutic antibodies, 26,27 the resistence of B.1.526 may render 376 these treatments ineffective despite their prior success against other variants, leading to 377 increases in IFR among older adults. These findings highlight the importance of monitoring the 378 efficacy of therapeutics against different variants and timely update of treatments. In addition, 379 a better understanding of factors contributing to the higher IFRs in certain variants is warranted 380 to inform countermeasures. 28,29 381 382 Lastly, our analyses suggest both B.1.526 and B.1.1.7 likely had been spreading in the 383 population for weeks or months prior to detection by the surveillance system. 2,3,30 Expanding 384 genomic sequencing programs for SARS-CoV-2 and improving linkage to epidemiologic data can 385 improve detection of new VOIs/VOCs. Such efforts are underway (e.g., in the US) but more 386 efforts and resources are urgently needed globally. In addition, to support more timely 387 detection and control, targeted screening of key subpopulations (e.g., those prospectively 388 identified from modeling as having high transmission rates) and viral traits (e.g., mutations 389 linked to increased transmissibility and/or immune evasion as done in Annavajhala et al. 2 ) is 390 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint needed, as well as timely sharing of key information globally. The documentation of new 391 VOIs/VOCs anywhere in the world then should prompt preparedness measures to detect and 392 rapidly respond to the introduction of those variants into local areas. More fundamentally, to 393 limit emergence of new VOIs/VOCs and end the COVID-19 pandemic, all populations worldwide 394 should have timely access to vaccination, and multiple layers of mitigation efforts are needed 395 until a sufficient portion of the population is protected by vaccination. Our study also has several limitations. First, most of our analyses are based on population-level 398 data without variant-specific information, given limited variant testing during most of the study 399 period. We circumvented this data deficiency by analyzing estimates of a key subpopulation 400 (e.g., the WHts neighborhood where B. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. White crosses (x) indicate the best-performing parameter combination. Right panel shows 563 model estimates using the overall best-performing parameter combination (i.e., 1.5-3.5% initial 564 prevalence, 15-25% higher transmissibility, and 0-10% immune escape). Lines and surrounding 565 areas show model-simulated median estimates and interquartile range; dots show 566 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint corresponding observations; colors indicate different variants as specified in the legend. Note 567 that these model simulations used same infection-detection rate, hospitalization-rate and IFR 568 (i.e., average during Nov 2020 -Apr 2021); that is, they did not account for changes in case 569 ascertainment or disease severity by week during this period, due to, e.g., increases in disease 570 severity by the new variants. As such, there were larger deviations from the observations 571 during later months of the simulation with more infections by the new variants. to Apr 25, 2021. X-axis labels show the week starts (mm/dd/yy). 577 578 579 Supplemental Table and Figure Captions 580 Table S1 . Prior ranges for the network model-inference system. The prior ranges are similar to 581 Table S1 of Yang et al. 1 but include additional parameters in Eqn 1. The spatial, temporal, and 582 age resolution of each parameter or variable, estimated in the model-inference system, is 583 specified in the column "Resolution". Note posterior parameter estimates can extend outside 584 the specified prior ranges. 585 586 Table S2 . Initial conditions used to simulate co-circulation of different variants in the multi-587 variant, age-structured model. To partially account for changing infection-detection rate, ED-588 consultation rate (EDR) and IFR, for these three parameters, we used the model-inference 589 estimates averaged over the entire simulation period (i.e. Nov 2020 -April 2021). For the initial 590 transmission rate (for the preexisting non-VOC/VOI variants), we used the model-inference 591 estimates averaged over the week of 10/25/2020 -the week of 11/7/2020 (i.e. the 3 weeks 592 around the start of simulation). For the rest of model state variables and parameters, we used 593 model-inference estimates made at the week of 10/25/2020. For B.1.1.7, we used the 594 following ranges based on estimates from Yang and Shaman 10 : 40.3 -52.3% higher 595 transmissibility (related to estimates for the preexisting non-VOC/VOI variants listed below) and 596 0 -10% immune escape; for comparison, contact tracing data from the UK showed that B. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 526-related IFR and B.1.1.7 Model-inference estimates of overall IFR used as predictands All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint White crosses (x) indicate the best-performing parameter combination. Right panel shows 655 model estimates using the overall best-performing parameter combination (i.e., 1.5-3.5% initial 656 prevalence, 15-25% higher transmissibility, and 0-10% immune escape). Lines and surrounding 657 areas show model-simulated median estimates and interquartile range; dots show 658 corresponding observations; colors indicate different variants as specified in the legend. Note 659 that these model simulations used same infection-detection rate, hospitalization-rate and IFR 660 (i.e., average during Nov 2020 -Apr 2021); that is, they did not account for changes in case 661 ascertainment or disease severity by week during this period, due to, e.g., increases in disease 662 severity by the new variants. As such, there were larger deviations from the observations 663 during later months of the simulation with more infections by the new variants. 664 Weekly cases Weekly hospitalizations 1 1 / 0 1 / 2 0 1 1 / 2 9 / 2 0 1 2 / 2 7 / 2 0 0 1 / 2 4 / 2 1 0 2 / 2 1 / 2 1 0 3 / 2 1 / 2 1 0 4 / 1 8 / 2 1 1 1 / 0 1 / 2 0 1 1 / 2 9 / 2 0 1 2 / 2 7 / 2 0 0 1 / 2 4 / 2 1 0 2 / 2 1 / 2 1 0 3 / 2 1 / 2 1 0 4 / 1 8 / 2 1 1 1 / 0 1 / 2 0 1 1 / 2 9 / 2 0 1 2 / 2 7 / 2 0 0 1 / 2 4 / 2 1 0 2 / 2 1 / 2 1 0 3 / 2 1 / 2 1 0 4 / 1 8 / 2 1 1 1 / 0 1 / 2 0 1 1 / 2 9 / 2 0 1 2 / 2 7 / 2 0 0 1 / 2 4 / 2 1 0 2 / 2 1 / 2 1 0 3 / 2 1 / 2 1 0 4 / 1 8 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint Supplemental Tables and Figures 672 Table S1 . Prior ranges for the network model-inference system. The prior ranges are similar to 673 Based on R0 estimates of around 1.5-4 for SARS-CoV-2 4-6 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint Table S3 . Estimated IFR for different variants and changes compared to the baseline risk 697 estimated for preexisting variants during Oct -Dec 2020, using Eqn 3. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 7, 2021. ; https://doi.org/10.1101/2021.08.04.21261596 doi: medRxiv preprint 526 (%) Changes, B.1.526 (%) Model fit Estimating the infection-fatality risk of SARS-CoV-2 in 701 New York City during the spring 2020 pandemic wave: a model-based analysis. The Lancet 702 Infectious diseases New York City Department of Health and Mental Hygiene. NYC DOHMH population 704 estimates, modified from US Census Bureau interpolated intercensal population estimates Social contacts and mixing patterns relevant to the spread of 707 infectious diseases Early Transmission Dynamics in Wuhan, China Coronavirus-Infected Pneumonia Nowcasting and forecasting the potential domestic and 711 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling 712 study Substantial undocumented infection facilitates the rapid 714 dissemination of novel coronavirus (SARS-CoV-2) Evolving epidemiology and transmission dynamics of 716 coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study A simple modification for improving inference of non-linear dynamical 719 systems Estimates of the severity of coronavirus disease 2019: a 721 model-based analysis Epidemiological characteristics of three SARS-CoV-2 variants of concern 723 and implications for future COVID-19 pandemic outcomes Investigation of novel SARS-CoV-2 variant, Variant of Concern 726 202012/01, Technical briefing 3 Transmission, infectivity, and antibody 728 neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike 729 protein mutation Red lines show the estimated median 732 infection-detection rate with surrounding areas indicating the 50% (darker color) and 95% 733 (lighter color) CrI. For comparison, the grey bars show the number of cases reported for each 734 week from the week of Boxes show model estimates (thick horizontal lines and box 739 edges show the median, 25 th , and 75 th percentiles; vertical lines extending from each box show 740 95% Crl) and red dots show corresponding Estimated cumulative infection rates by age group. Thick horizontal lines and box edges 743 show the median, 25 th , and 75 th percentiles